Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities effective December 31, 2018. Per Falk, Chief Science Officer, will assume additional responsibility as President of the Executive Committee, effective January 1, 2019. Michel has had an exceptional career at Ferring, taking the company from revenues of €345 million when he joined the company in 2001 to nearly €2 billion to...